The robust Phase 3 data support a high probability of regulatory approval and commercial success, especially given the early and deep clinical responses and favorable safety. Traders should monitor the upcoming NDA submission and FDA feedback. Positive read-through to envudeucitinib's potential in lupus (LUMUS trial, topline data Q3 2026) is likely.
Price Chart
Executive Summary
Alumis Inc. announced positive Phase 3 results for envudeucitinib, a highly selective oral TYK2 inhibitor, in moderate-to-severe plaque psoriasis. The drug demonstrated robust skin clearance (PASI 90: 68.0% and 62.1%; PASI 100: 41.0% and 39.5%) by Week 24, with early onset of symptom relief and a favorable safety profile. The company plans to submit a New Drug Application (NDA) to the FDA in the second half of 2026.
Key Facts
- Envudeucitinib achieved PASI 90 responses in 68.0% and 62.1% of patients by Week 24 across two Phase 3 trials (ONWARD1 and ONWARD2).
- PASI 100 (complete skin clearance) was achieved by 41.0% and 39.5% of patients by Week 24.
- Clear or almost clear scalp psoriasis (ss-PGA 0/1) was achieved by ~75% of patients by Week 24, with responses as early as Week 4.
- Quality-of-life (DLQI 0/1) and itch relief (Worst Pruritus NRS) improvements emerged early and deepened through Week 24.
- Safety profile was favorable, consistent with Phase 2, with no new safety signals or tuberculosis reactivation.
- NDA submission planned for second half of 2026.
Financial Impact
High commercial potential given strong efficacy and oral dosing in a $3B+ market for psoriasis treatments; could capture significant share if approved.
Risk Factors
- Regulatory rejection or delay of NDA submission or approval.
- Competition from existing biologics and other TYK2 inhibitors (e.g., deucravacitinib).
- Long-term safety data still maturing; rare adverse events may emerge in broader use.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3264196 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 6w ago | Insider Buy | $9.90 $9.18 | ▼ −7.27% | ▼ −8.13% | $6.64 (−32.93%) |
Sep 1, 2026 8w ago | 8-K | $9.47 $10.35 | ▲ +9.29% | ▲ +8.85% | $6.64 (−29.88%) |
Aug 15, 2026 10w ago | Institutional Cluster | $25.50 $24.88 | ▼ −2.43% | ▼ −1.76% | $6.64 (−73.96%) |
Aug 10, 2026 11w ago | 8-K | $25.37 $25.55 | ▲ +0.71% | ▲ +0.46% | $6.64 (−73.83%) |
Aug 5, 2026 11w ago | Insider Cluster | $27.80 $27.60 | ▼ −0.72% | ▼ −1.33% | $6.64 (−76.12%) |
Aug 5, 2026 11w ago | Insider Cluster | $27.80 $27.60 | ▼ −0.72% | ▼ −1.33% | $6.64 (−76.12%) |
Jun 29, 2026 17w ago | 8-K | $27.14 $28.14 | ▲ +3.68% | ▲ +2.91% | $6.64 (−75.53%) |
Jun 11, 2026 19w ago | Institutional Cluster | $20.90 $24.15 | ▲ +15.55% | ▲ +15.01% | $6.64 (−68.23%) |
May 18, 2026 23w ago | DEFA14A | $21.53 $22.04 | ▲ +2.39% | ▲ +1.35% | $6.64 (−69.15%) |
Mar 28, 2026 30w ago | Press Release | $20.21 $22.03 | ▲ +9.01% | ▲ +6.11% | $6.64 (−67.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers